Elion nets $81M to fund development of antifungal with lower toxicity risks

### Title
Elion Therapeutics Secures $81 Million in Funding for Novel Antifungal Agent with Lower Toxicity Risks
### Keywords
- Elion Therapeutics
- Antifungal Agent
- Lower Toxicity Risks
- Series B Funding
### Key Facts
1. Funding Amount: Elion Therapeutics has secured $81 million in funding.
2. Purpose: The funding is for the development of a novel antifungal agent with lower toxicity risks.
3. Type of Funding: The funding is a Series B round.
4. Source: The information was reported by PR Newswire.